Scarica l'app Stockscreener
1.4982
12.60%
0.1882
Aspire Biopharma Holdings Inc Borsa (ASBP) Ultime notizie
Aspire Biopharma appoints Phillip Balatsos to board of directors - Investing.com
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors - itemonline.com
Veteran markets executive joins Aspire to push rapid-onset drug platform - Stock Titan
Aspire Biopharma secures up to $21M in convertible preferred stock financing - MSN
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Worcester Telegram
Aspire Biopharma Announces Private Placement to Strengthen Finances - TipRanks
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - BlueRidgeNow.com
Aspire Biopharma Holdings Signs Multiple Material Agreements - TradingView
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - ACCESS Newswire
New Zofran-style powder aims to bring IV-speed nausea relief at home - Stock Titan
Major Financial Concerns Loom as Aspire Biopharma Troubles Deepen - StocksToTrade
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - ACCESS Newswire
$21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan
Aspire Biopharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Canada
Aspire Biopharma Announces Reverse Stock Split - SouthCoastToday.com
Aspire Biopharma Provides Q3 2025 Business Update - Corpus Christi Caller-Times
Aspire Biopharma regains Nasdaq minimum bid price compliance - MSN
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - itemonline.com
ASBP Stock Price, Forecast & Analysis | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - accessnewswire.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - DelmarvaNow.com
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Yahoo Finance
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - The Times-Mail
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Finviz
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - The Clarion-Ledger
ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - stocktitan.net
0.71%
1.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):